Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for the weight loss pill.

Eli Lilly said its tirzepatide franchise had another stellar quarter.

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared with Novo Nordisk’s rival Wegovy pill.

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage myelofibrosis therapy. | Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up,

Eli Lilly is set to post earnings Thursday morning, with the stock seen potentially sinking to its lowest level in months following the report.

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 earnings. Net income increased 155% to $7.66bn, and for good measure, the Pharma increased its 2026 guidance to $82bn-$85bn of revenues,

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO) now offers a more compelling setup than GLP-1 category leader Eli Lilly (NYSE:LLY) after a peak-to-current decline of roughly 68% from Novo’s mid-2024 high near $127 to recent levels near $40.